Long term oral anticoagulant therapy after heart valve prostheses at Siriraj Hospital.

Simple item page
dc.contributor.authorTalalak, Pen_US
dc.contributor.authorBhakeecheep, Sen_US
dc.contributor.authorChotmonggol, Ven_US
dc.contributor.authorPrachubmoh, Ken_US
dc.contributor.authorOpartkiattikul, Nen_US
dc.date.accessioned2009-05-27T20:18:58Z
dc.date.available2009-05-27T20:18:58Z
dc.date.issued1989-05-01en_US
dc.descriptionChotmaihet Thangphaet.en_US
dc.description.abstractOne hundred and forty-six cases of cardiac valvular prostheses in the Department of Surgery, Siriraj hospital, were studied retrospectively for the effect of long-term oral anticoagulant therapy. Warfarin sodium was given to 119 patients after operation, 5 cases discontinued therapy and 27 cases received no anticoagulant at all due to loss of follow-up. One stage prothrombin time was used as laboratory control. The advocated therapeutic range for commercial rabbit brain thromboplastin was 1.35-2.2 P.T. ratio. The incidence of thromboembolism was 8.9 per 100 patients - year in the nontherapeutic group, and was 0.6 per 100 patients - year in the therapeutic group (p less than 0.05). Bleeding complications was 26.9 per cent. These were 34 minor-, 11 major-and 2 fatal bleeding episodes. One bleeding manifestation was found in the nontherapeutic group, the etiology was not recorded. The mean dose of warfarin sodium in the thromboembolic group was 2.5 mg/day, this gave a therapeutic ratio of less than 1.4. In the bleeding group that had P.T. ratio not exceeding 2.2, the mean dose was 3.37 mg/day; and 5.23 mg/day when P.T. ratio was higher than 2.2 (p less than 0.01). Therefore, it seems justifiable to conclude that the appropriate mean dose should be over 2.5 mg/day and less than 3.37 mg/day. However, regular blood test to determine the appropriate daily dose for each individual patient is obligatory, as patients might be more or less sensitive to the drug than the average and drug requirement varies from time to time even in the same individual owing to many factors.(ABSTRACT TRUNCATED AT 250 WORDS)en_US
dc.identifier.citationTalalak P, Bhakeecheep S, Chotmonggol V, Prachubmoh K, Opartkiattikul N. Long term oral anticoagulant therapy after heart valve prostheses at Siriraj Hospital. Journal of the Medical Association of Thailand. 1989 May; 72(5): 250-4en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/42771
dc.language.isoengen_US
dc.source.urihttps://www.mat.or.th/journal/all.phpen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAnticoagulants --administration & dosageen_US
dc.subject.meshAortic Valve --surgeryen_US
dc.subject.meshChilden_US
dc.subject.meshFemaleen_US
dc.subject.meshHeart Valve Prosthesisen_US
dc.subject.meshHumansen_US
dc.subject.meshLong-Term Careen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMitral Valve --surgeryen_US
dc.subject.meshPostoperative Careen_US
dc.subject.meshTricuspid Valve --surgeryen_US
dc.titleLong term oral anticoagulant therapy after heart valve prostheses at Siriraj Hospital.en_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Medical Association of Thailand